香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年11月7日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 江苏恒瑞医药股份有限公司（以下简称"公司"）2022 年员工持股计划第三 个锁定期已于 2025 年 11 月 7 日届满，根据中国证监会《关于上市公司实施员工 持股计划试点的指导意见》以及《上海证券交易所 ...

Core Viewpoint - Heng Rui Medicine (01276) announced the transfer of 13.51 million A-shares, which were repurchased, to an employee stock ownership plan on November 7, 2025 [1] Group 1 - The company will transfer a total of 13.51 million A-shares to the employee stock ownership plan [1]

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 A | | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | 600276 | 說明 | A股（於上海證券交易所上市） | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 佔有關事件前的現有已發 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | | | | 於下列日期開始時的結存(註1) | 2025年11月4日 | 6,362, ...

Core Insights - The rapid development of China's biopharmaceutical sector is prompting multinational pharmaceutical companies (MNCs) to adjust their strategies, focusing on increasing investment in the Chinese market and accelerating the introduction of global innovative products into China [1][2] - MNCs are adopting a dual strategy of enhancing local market engagement while leveraging Chinese innovations to expand globally, as highlighted by GSK and Kelsey Group's approaches [1][2][3] Group 1: Investment and Collaboration - The top 20 MNCs have steadily increased the number and value of assets introduced from China since 2021, with a total of $39.4 billion in innovative drug assets introduced in the first eight months of 2025, accounting for 37.4% of global transaction totals [2] - In the first three quarters of 2025, the total amount for Chinese license-out transactions reached $92.03 billion, indicating a vibrant BD transaction environment for domestic innovative drugs [2] - GSK's strategic partnership with Heng Rui Pharmaceutical involves the joint development of up to 12 innovative drugs, with GSK committing a total of $500 million in upfront payments and potential milestone payments of approximately $12 billion [2][3] Group 2: Market Dynamics and Growth - Kelsey Group's strategy includes three pillars: China to China, Global to China, and China to Global, emphasizing increased investment in the Chinese market and the integration of Chinese innovations into its global system [1][2] - Kelsey Group's recent collaboration with Haisco on the innovative drug HSK31858 represents a significant step in bringing Chinese innovations to global markets, particularly in treating chronic airway diseases [3] - The Chinese market is becoming a key growth engine for GSK, with expectations that approximately 18 new products and indications will be approved in China over the next three years [9] Group 3: Strategic Initiatives and Future Outlook - MNCs are increasingly focusing on enhancing their R&D presence in China, with Kelsey Group planning to increase its R&D personnel and strengthen its engagement with the local innovation ecosystem [4][6] - Boehringer Ingelheim's strategy includes a planned investment of over 5 billion RMB in R&D in China over the next five years, focusing on areas such as metabolism, inflammation, eye health, and oncology [8] - The China International Import Expo (CIIE) is recognized as a vital platform for MNCs to showcase innovations and deepen collaborations, with Boehringer Ingelheim highlighting its commitment to open innovation through this event [7][8]

Core Insights - The article highlights the top and bottom AH premium rates for various stocks as of November 7, with Northeast Electric (00042) leading with a premium rate of 881.82% [1] - The article also provides a detailed ranking of stocks based on their deviation values, indicating significant discrepancies between H-shares and A-shares [1] AH Premium Rate Rankings - The top three stocks with the highest AH premium rates are: - Northeast Electric (00042): H-share at 0.275 HKD, A-share at 2.25 CNY, premium rate of 881.82%, deviation value of 47.50% [1] - Hongye Futures (03678): H-share at 3.600 HKD, A-share at 10.95 CNY, premium rate of 264.44%, deviation value of 26.95% [1] - Sinopec Oilfield Service (01033): H-share at 0.770 HKD, A-share at 2.31 CNY, premium rate of 259.74%, deviation value of 23.17% [1] - The bottom three stocks with the lowest AH premium rates are: - CATL (03750): H-share at 558.500 HKD, A-share at 395.37 CNY, premium rate of -15.21%, deviation value of 1.62% [1] - China Merchants Bank (03968): H-share at 51.250 HKD, A-share at 42.51 CNY, premium rate of -0.64%, deviation value of -2.86% [1] - Heng Rui Medicine (01276): H-share at 69.950 HKD, A-share at 61.74 CNY, premium rate of 5.72%, deviation value of 7.04% [1] Deviation Value Rankings - The top three stocks with the highest deviation values are: - Northeast Electric (00042): premium rate of 881.82%, deviation value of 47.50% [1] - Hongye Futures (03678): premium rate of 264.44%, deviation value of 26.95% [1] - Changfei Optical Fiber (06869): premium rate of 189.56%, deviation value of 26.59% [1] - The bottom three stocks with the lowest deviation values are: - COSCO Shipping Energy (01138): premium rate of 41.17%, deviation value of -13.87% [2] - China Eastern Airlines (00670): premium rate of 37.91%, deviation value of -11.53% [2] - China Life Insurance (02628): premium rate of 103.35%, deviation value of -11.12% [2]

Core Insights - Wellington Management Group LLP increased its stake in Heng Rui Medicine (恒瑞医药) by purchasing 855,600 shares at an average price of HKD 72.6411 per share, totaling approximately HKD 62.15 million [1] - Following this transaction, Wellington Management's total shareholding in Heng Rui Medicine rose to 18,462,687 shares, increasing its ownership percentage from 6.82% to 7.15% [1] Summary by Category Shareholding Changes - Wellington Management Group LLP acquired 855,600 shares of Heng Rui Medicine, raising its total holdings to 18,462,687 shares [1] - The ownership percentage increased from 6.82% to 7.15% after the purchase [1] Financial Details - The total investment for the share purchase was approximately HKD 62.15 million [1] - The average purchase price per share was HKD 72.6411 [1]

| 股份代號: | 01276 | | --- | --- | | 上市法國名稱: | 江蘇恒瑞醫藥股份有限公司 - H股 | | 日期 (日 / 月 / 年): | 07/10/2025 - 07/11/2025 | 增持后，Wellington Management Group LLP最新持股数目为18,462,687股，持股比例由6.82%上升至7.15%。 格隆汇11月7日丨根据联交所最新权益披露资料显示，2025年11月4日，恒瑞医药(01276.HK)获Wellington Management Group LLP在场内以每股均价72.6411港 元增持85.56万股，涉资约6215.17万港元。 | 表格序號 | 大股東/董事/最高行政人員名 作出披露的 買入 / 賣出或涉及的 每股的平均價 | | | | 持有權益的股份數目 佔已發行的有關事件的日 相關 | | --- | --- | --- | --- | --- | --- | | | 股份數目 | 間天 | | | ( 請參閱上述 * 註 有 投票權股 期 (日 / 月 / 年)權益 | | | | | | | 份自分比 | | | | ...

Core Viewpoint - Wellington Management Group LLP has increased its stake in 恒瑞医药 (Hengrui Medicine) by acquiring 855,600 shares at a price of HKD 72.6411 per share, totaling approximately HKD 62.1517 million, raising its total holdings to about 18.4627 million shares, which represents a 7.15% ownership stake [1] Summary by Category - **Share Acquisition** - Wellington Management Group LLP purchased 855,600 shares of 恒瑞医药 at HKD 72.6411 per share [1] - The total investment amounts to approximately HKD 62.1517 million [1] - **Ownership Details** - After the acquisition, Wellington Management's total shareholding in 恒瑞医药 is approximately 18.4627 million shares [1] - This represents a 7.15% ownership stake in the company [1]

Core Insights - The 8th China International Import Expo (CIIE) opened in Shanghai on November 5, 2023, with the theme "Open Up to Create New Opportunities, Collaborate to Share a New Future," attracting participation from 155 countries and regions, with over 4,108 foreign enterprises exhibiting, marking a new high in scale [1][3] Industry Developments - Multinational pharmaceutical companies are increasingly establishing R&D centers in China, with Astellas announcing its first innovation R&D center in Beijing on October 27, 2023, complementing its existing centers in Tokyo, San Francisco, Boston, Chicago, and Cambridge [3][4] - Major pharmaceutical companies like AstraZeneca and Boehringer Ingelheim have announced new investment plans in China, with AstraZeneca planning to invest $2.5 billion (approximately 18 billion RMB) and Boehringer Ingelheim over 5 billion RMB [4][5] - The trend of multinational companies acquiring innovative drug assets in China is accelerating, with companies like Takeda and Pfizer making significant investments to secure innovative drug assets, setting new records for business development (BD) transaction volumes in the Chinese innovative drug market [4][5] Market Positioning - China is evolving from a passive consumer market to a global innovation hub for multinational pharmaceutical companies, participating deeply in the entire process from R&D to production and sales [5][6] - By 2024, over 20% of the top 100 life sciences research institutions in the Nature Index will be in China, and the number of clinical trials initiated in China is expected to approach 2,000, reflecting a significant increase in China's innovation capabilities [6][7] Collaborative Trends - The number of multinational pharmaceutical companies establishing R&D centers in China has surged, with at least eight companies announcing new centers in October 2023 alone, including Eli Lilly, Pfizer, Bayer, and AstraZeneca [8][9] - Eli Lilly has invested over 20 billion RMB in China, focusing on a full industry chain layout from R&D to commercialization, and plans to continue expanding its local collaborations [10][11] Investment and Business Development - The total amount of innovative drug licensing agreements from China has surpassed $100 billion, with significant growth in transaction volumes and values, indicating a robust BD trend in the Chinese pharmaceutical market [15][16] - Notable transactions include Pfizer's $12.5 billion upfront payment for a breakthrough drug and Takeda's recent collaboration with Innovent Biologics involving a potential total deal value of up to $11.4 billion [16][17] Future Outlook - The trend of multinational companies seeking innovative resources in China is expected to continue, driven by the need to fill revenue gaps due to patent expirations in the U.S. and Europe [18][19] - The influence of Chinese biotech on the global market is growing, with projections indicating that by 2040, 35% of FDA-approved innovative drugs may originate from China [19]